SRT1720 treatment directly reduced the expression of lipogenic genes, such as SREBP-1c, ACC, and FAS, reduced liver lipid accumulation, and reduced oxidative stress and inflammation, which improved the development of NAFLD in monosodium-glutamate (MSG)-induced diabetic mice [53]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.